Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.51 |
| ▸ | LAP3 | P28838 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9628017 | 1.00 | NOD1 (0.58) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| SCHEMBL13585300 | 1.00 | NOD1 (0.58) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| SCHEMBL234160 | 1.00 | NOD1 (0.58) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| SCHEMBL13585297 | 1.00 | NOD1 (0.58) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Glutamic Acid SCHEMBL4393021 | 0.95 | FOLH1 (0.60) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| D-Glutamate SCHEMBL4393018 | 0.95 | FOLH1 (0.60) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Glutamine SCHEMBL4395724 | 0.94 | KMT2A (0.56) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Glutamine SCHEMBL4395718 | 0.94 | KMT2A (0.56) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Aspartic Acid SCHEMBL4390861 | 0.93 | NOD1 (0.52) | NOD1ALDH1A1FOLH1PTGS1GSTK1 | |
| Aspartic Acid SCHEMBL4390865 | 0.93 | NOD1 (0.52) | NOD1ALDH1A1FOLH1PTGS1GSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| US-12370173-B2 | Pet food compositions that modulate vitamin D and bone mineral content in a companion animal | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-07-29 | — | — | US | claimed |
| CN-114269951-B | Diagnostic method for aesthetic deterioration of skin | 欧莱雅 | 2024-12-27 | — | — | CN | claimed |
| EP-3969903-B1 | METHOD OF SELECTING SKIN TREATMENT REGIMENS, INGREDIENTS AND COMPOSITIONS | JOHNSON & JOHNSON CONSUMER INC (US) | 2024-10-09 | — | — | EP | claimed |
| CN-118655322-A | Metabolic-study-based breast cancer detection biomarker and application thereof | 浙江大学 | 2024-09-17 | — | — | CN | claimed |
| CN-118632858-A | Gastric inhibitory peptide receptor ligands | 3B制药有限公司 | 2024-09-10 | — | — | CN | claimed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-20240165006-A1 | DERMATOLOGICAL COMPOSTIONS AND USE THEREOF | BONE SCI. BIO LTD. (IL) | 2024-05-23 | — | — | US | claimed |
| EP-3865591-B1 | SET OF BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME | CARDIOMIX S R L (IT) | 2024-04-03 | — | — | EP | claimed |
| US-8658351-B2 | Determining liver toxicity of an agent using metabolite biomarkers | METABOLON, INC. (US) | 2014-02-25 | — | — | US | claimed |
| WO-2013188333-A1 | BIOMARKERS RELATED TO NEPHROTOXICITY AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-12-19 | — | — | WO | claimed |
| WO-2013039898-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| WO-2012164525-A2 | AGING BIOMARKERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2012-12-06 | — | — | WO | claimed |
| US-20120122981-A1 | Biomarkers Related to Insulin Resistance and Methods using the Same | METABOLON, INC. | 2012-05-17 | — | — | US | claimed |
| EP-2414535-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | Metabolon Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| WO-2010114897-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-5126245-A | REAGENTS FOR ASSAY OF GAMMA-GLUTAMYLTRANSPEPTIDASE | UNITIKA LTD. (JP) | 1992-06-30 | — | — | US | claimed |
| EP-0266905-A1 | Reagents for assay of gamma-glutamyl-transpeptidase | UNITIKA LTD. (JP) | 1988-05-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | NOD1 643/4885ALDH1A1 3223/4885FOLH1 661/4885 |
| US-12370173-B2 | Pet food compositions that modulate vitamin D and bone mineral content in a companion animal | CYP24A1, GC, VDR | NOD1 3849/4885ALDH1A1 3672/4885FOLH1 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.